On the back of reporting megablockbuster sales of Wegovy, Novo Nordisk has snapped up Inversago Pharma for up to $1.075 billion in a deal that will see the company further lean into its weight loss domain.
Novo Nordisk revealed the buyout during its second-quarter results call with the media, noting the acquisition “supports its aspiration within obesity and other metabolic disorders.” It didn’t break down the upfront and milestones during the call.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.